Örmeci N, et al. - In this multicenter, retrospective cohort study, researchers presented real-life experiences of hepatitis C virus infection (HCV) and chronic kidney disease (CKD) treatment with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day as a PROD regimen. Findings revealed that 96% of patients found sustained viral rate 12 weeks after treatment. In patients with HCV and CKD who were in stages 4 and 5, the PROD regimen was very effective and safe for treatment.